[Manifestation of myotonic disturbances of muscle function under continuous intravenous drip treatment with the beta-adrenergic th 1165 a (fenoterolhydrobromide) (author's transl)].
D000318:Adrenergic beta-Agonists / Q000009:adverse effects*; D000328:Adult; D001965:Bromides / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009921:Metaproterenol / Q000009:adverse effects / Q000031:analogs & derivatives*; D009223:Myotonic Dystrophy / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics*; D010636:Phenols / Q000009:adverse effects; D010672:Phenytoin / Q000627:therapeutic use; D010923:Placenta Previa / Q000188:drug therapy*; D011247:Pregnancy; D013577:Syndrome
D000318:Adrenergic beta-Agonists; D001965:Bromides; D010636:Phenols; D009921:Metaproterenol; D010672:Phenytoin
Manifestation myotoner Muskelfunktionsstörungen unter intravenöser Dauertropfbehandlung mit dem Beta-Adrenergikum Th 1165 a (Fenoterolhydrobromid)